Management Initiatives for the Medical Industry
Management Initiatives for the Medical Industry
Management Initiatives for the Medical Industry
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Sep 27, 2010<br />
Open Course 2010<br />
<strong>Management</strong> <strong>Initiatives</strong> <strong>for</strong> <strong>the</strong> <strong>Medical</strong> <strong>Industry</strong><br />
Presented by <strong>the</strong> University of Tokyo Global COE program “Center <strong>for</strong> <strong>Medical</strong> System Innovation (CMSI)” (Course Manager: Pharmaco-Business Innovation)<br />
[Date] October 26, 2010– March 22, 2011<br />
[Time] 18:00 – 21:00<br />
[Location] Tetsumon Memorial Hall (14 th Floor, Faculty of Medicine Experimental Research Building)<br />
Map: http://www.u-tokyo.ac.jp/campusmap/cam01_02_09_e.html<br />
[Target Audience] - Healthcare Professionals from <strong>Medical</strong> Institutes; Academic Society; Healthcare <strong>Industry</strong> including Pharmaceuticals and <strong>Medical</strong> device<br />
companies<br />
- Under- and post- graduate students (including CMSI students)<br />
- O<strong>the</strong>r professionals with a strong interest in contemporary dynamics in <strong>the</strong> medical industry<br />
[No. of Participants] 200<br />
[Course description] This course consists of a series of unique lectures by authoritative leaders from medical institutions, universities, research institutes and<br />
healthcare corporations. Each lecture focuses on recent structural dynamics in medical and healthcare systems.<br />
In June this year, <strong>the</strong> new Japanese government <strong>for</strong>mulated a new growth strategy “Blueprint <strong>for</strong> Revitalizing Japan” to revive <strong>the</strong> Japanese<br />
economy. As part of this strategic intent, medical and healthcare initiatives are expected to be key drivers <strong>for</strong> boosting t economic growth,<br />
because Japan has a “Science & Technology” advantage and "Monozukuri” which are significant foundations <strong>for</strong> developing new life-science<br />
innovation.<br />
To actualize this new growth strategy, we will examine a broad set of issues including policy, corporate management, global strategy, R&D,<br />
and innovation, as well as discussing <strong>the</strong> foundations <strong>for</strong> creating <strong>the</strong> state of <strong>the</strong> art life-science innovation.<br />
[Registration] Please write 1) your name, 2) name of your company (school), 3) telephone number and 4) e-mail address, and send by e-mail to<br />
pbi-seminar@mol.f.u-tokyo.ac.jp.<br />
[Payment <strong>for</strong> Course Registration] 50,000 yen UT Students: Free Students from o<strong>the</strong>r universities: 20,000 yen<br />
[Organization Office]<br />
Pharmaco-Business Innovation, Graduate School of Pharmaceutical Sciences, <strong>the</strong> University of Tokyo<br />
7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033 Japan<br />
Professor: Hiromichi Kimura Associate Professor: Sachiko Masuda<br />
Contact: Yoko Takahashi, Naoko Iita, Yuko Mochida<br />
Tel: +81-3-5842-2454 E-mail: pbi-seminar@mol.f.u-tokyo.ac.jp<br />
URL: http://www.f.u-tokyo.ac.jp/~pbi/index.htm<br />
1
Schedule might be changed on <strong>the</strong> basis of lecturers’ schedule<br />
Date Lecture Title Speaker Affiliation Title<br />
1 Oct.26th (Tue.)<br />
Introduction<br />
New Growth<br />
Strategy<br />
Hiromichi Kimura<br />
Yosuke Kondo<br />
Graduate School of<br />
Pharmaceutical Sciences<br />
The University of Tokyo<br />
Member of <strong>the</strong> House of<br />
Representatives<br />
Professor<br />
The <strong>for</strong>mer Vice Minister of Economy, Trade and <strong>Industry</strong><br />
2 Nov.9th (Tue.)<br />
3 Nov.24th (Wed.)<br />
4 Dec.7th (Tue.)<br />
5 Dec.21st (Tue.)<br />
6 Jan.11th (Tue.)<br />
7 Jan.25th (Tue.)<br />
The Front Lines of<br />
Cancer Treatment<br />
National Security<br />
(Infectious disease)<br />
Global Life Science<br />
Innovation<br />
Strategy <strong>for</strong> new<br />
drug<br />
Challenge <strong>for</strong><br />
Innovative Medicine<br />
Med-term View of<br />
Pharmaceutical<br />
Companies<br />
8 Feb.8th (Tue.) <strong>Medical</strong> Devices<br />
9 Mar.1st (Tue.) Cluster<br />
10 Mar.22nd (Tue.) Innovation<br />
Tetsuichiro Muto<br />
Hiroyasu Esumi<br />
Masato Iwasaki<br />
JAPANESE FOUNDATION<br />
FOR CANCER RESEARCH<br />
National Cancer Center<br />
Hospital East<br />
Takeda Pharmaceutical<br />
Company Ltd.<br />
Executive Director, <strong>Medical</strong> Director,<br />
The <strong>for</strong>mer Director<br />
Corporate Officer, Senior Vice President, Strategic Product<br />
Planning Department<br />
Shigeru Omi Jichi <strong>Medical</strong> University Professor, Public Health, Center <strong>for</strong> Community Medicine<br />
Bruce Howard U.S. Embassy in Japan<br />
Unit Chief, Environment, Science, Technology and Health<br />
Unit, Economic Section<br />
Chris Pook British Embassy Tokyo Counsellor, Science & Innovation Section<br />
Hideo Utsumi<br />
Pharmaceutical and <strong>Medical</strong><br />
Devices Agency<br />
Executive Director<br />
Director, Center <strong>for</strong> Product Evaluation<br />
Ichiro Umeda Pfizer Japan Inc. President & Chief Executive Officer<br />
Kentaro Yoshimatsu Eisai Co., Ltd. Senior Vice President, Chief Scientific Officer<br />
Tohru Yasukohchi NOF CORPORATION<br />
Tony Alvarez<br />
Banyu Pharmaceutical<br />
Co., Ltd.<br />
Ken Yamazumi Kyowa Hakko Kirin Co., Ltd.<br />
Kazuhisa Yanagisawa Olympus Corporation<br />
David W. Powell<br />
Johnson & Johnson K.K.<br />
<strong>Medical</strong> Company<br />
Takashi Miki City of KOBE<br />
Toshio Kuroki<br />
Gifu Research and<br />
Development Foundation<br />
Nobuhide Kobayashi Kawasaki City Office<br />
Koichi Kitazawa<br />
(TBD)<br />
Japan Science and Technology<br />
Agency<br />
General Manager, DDS Research Laboratory,<br />
DDS Development Division<br />
Representative Director and President<br />
Executive Director of <strong>the</strong> Board<br />
Executive Vice President<br />
Director, Member of <strong>the</strong> Board, Senior Executive Managing<br />
Officer, Group President, Corporate R&D Center<br />
President<br />
Director General, <strong>Medical</strong> <strong>Industry</strong> Development Project<br />
Planning and Coordination Bureau, City of KOBE<br />
Chief Director (Robotics Advanced <strong>Medical</strong> Cluster)<br />
Director , Kanagawa Gateway and Coastal Area<br />
Development Office,<br />
General Planning Bureau<br />
President<br />
2